Published in Cancer Res on September 15, 2012
The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol (2014) 2.52
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol (2015) 2.32
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2015) 1.85
Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res (2014) 1.51
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer (2014) 1.45
Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology (2013) 1.18
Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins. Proc Natl Acad Sci U S A (2015) 1.16
Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit. Clin Cancer Res (2013) 1.13
Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther (2014) 1.08
The link between androgen receptor splice variants and castration-resistant prostate cancer. Horm Cancer (2014) 1.05
Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630. PLoS One (2014) 0.98
Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer. Int J Biol Sci (2014) 0.95
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy. Onco Targets Ther (2014) 0.93
Interphase microtubules: chief casualties in the war on cancer? Drug Discov Today (2013) 0.85
Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. Clin Med Insights Urol (2013) 0.85
dCTP pyrophosphohydrase exhibits nucleic accumulation in multiple carcinomas. Eur J Histochem (2013) 0.84
Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer. Cancer Res (2015) 0.83
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics. Mol Cancer Ther (2016) 0.80
Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential. Mol Diagn Ther (2014) 0.79
A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and Repositioning Predictions. PLoS One (2015) 0.79
Plexin-B1 signalling promotes androgen receptor translocation to the nucleus. Oncogene (2015) 0.76
Mechanical aspects of microtubule bundling in taxane-treated circulating tumor cells. Biophys J (2014) 0.76
Interaction between c-jun and androgen receptor determines the outcome of taxane therapy in castration resistant prostate cancer. PLoS One (2013) 0.75
Role of androgen receptor splice variants in prostate cancer metastasis. Asian J Urol (2016) 0.75
Prognostic Significance and Functional Role of CEP57 in Prostate Cancer. Transl Oncol (2015) 0.75
Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS). Sci Rep (2016) 0.75
Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals. Oncogene (2016) 0.75
2-(m-Azidobenzoyl)taxol binds differentially to distinct β-tubulin isotypes. Proc Natl Acad Sci U S A (2016) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Microtubules as a target for anticancer drugs. Nat Rev Cancer (2004) 13.93
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell (2008) 6.62
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell (2010) 4.16
Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer (2007) 4.16
Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer (2010) 3.84
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell (2003) 3.66
Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res (2012) 3.35
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol (2000) 3.05
Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol (2011) 2.99
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res (2011) 2.69
Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol (2011) 2.61
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res (2010) 2.42
Microtubules and signal transduction. Curr Opin Cell Biol (1999) 2.21
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res (2011) 2.01
Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res (1998) 1.99
Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res (2009) 1.80
Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res (2011) 1.80
Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res (2011) 1.77
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci U S A (2002) 1.64
From signaling pathways to microtubule dynamics: the key players. Curr Opin Cell Biol (2009) 1.42
Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression. J Cell Biol (2011) 1.26
A microtubule-facilitated nuclear import pathway for cancer regulatory proteins. Traffic (2007) 1.22
Evidence for glucocorticoid receptor transport on microtubules by dynein. J Biol Chem (2004) 1.20
Nuclear transport of parathyroid hormone (PTH)-related protein is dependent on microtubules. Mol Endocrinol (2002) 1.17
Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. Int J Cancer (2008) 1.16
Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor. Clin Pharmacol Ther (2011) 0.96
Microtubules regulate hypoxia-inducible factor-1α protein trafficking and activity: implications for taxane therapy. J Biol Chem (2012) 0.95
Clinical significance of ABCB1 genotyping in oncology. J Oncol Pharm Pract (2009) 0.91
Knockdown of MBP-1 in human prostate cancer cells delays cell cycle progression. J Biol Chem (2006) 0.87
Lymphocyte signaling converges on microtubules. Immunity (2011) 0.83
Role of ERK1/2 activation in microtubule stabilization and glucose transport in cardiomyocytes. Am J Physiol Endocrinol Metab (2011) 0.79
The Treatment of Cancer of the Prostate : (The 1943 Address in Surgery before the Royal College of Physicians and Surgeons of Canada). Can Med Assoc J (1944) 0.79
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell (2003) 3.66
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol (2005) 3.01
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res (2011) 2.69
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip (2009) 2.56
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol (2012) 2.39
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol (2007) 2.36
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol (2004) 2.27
Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity. Chem Biol (2005) 2.11
Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents (2005) 2.10
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol (2007) 2.01
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol (2007) 1.95
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One (2012) 1.86
High expression of the Met receptor in prostate cancer metastasis to bone. Urology (2002) 1.83
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol (2009) 1.80
Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α. Cancer Res (2011) 1.75
Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol (2012) 1.68
Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res (2005) 1.67
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.64
The importance of p53 location: nuclear or cytoplasmic zip code? Drug Resist Updat (2003) 1.61
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer (2010) 1.57
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol (2003) 1.57
Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell (2004) 1.57
Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res (2014) 1.51
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res (2013) 1.51
Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res (2005) 1.49
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia (2013) 1.49
Interaction of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization, and cytotoxicity. Chem Biol (2004) 1.46
Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis. Cancer Res (2013) 1.46
The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry (2002) 1.45
Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues. J Med Chem (2007) 1.42
Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J Neurosci (2009) 1.37
HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano (2009) 1.29
Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell (2004) 1.28
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res (2005) 1.28
Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J Biol Chem (2005) 1.27
Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression. J Cell Biol (2011) 1.26
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol (2003) 1.24
EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle (2008) 1.23
Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res (2006) 1.23
Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem (2002) 1.22
Discovery of a biologically active thiostrepton fragment. J Am Chem Soc (2005) 1.20
Chemistry and biology of diazonamide A: second total synthesis and biological investigations. J Am Chem Soc (2004) 1.16
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med (2005) 1.14
Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer (2002) 1.14
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma. J Transl Med (2007) 1.12
Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta (2004) 1.10
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med (2005) 1.10
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res (2005) 1.08
Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther (2007) 1.07
Total synthesis of apoptolidin: completion of the synthesis and analogue synthesis and evaluation. J Am Chem Soc (2003) 1.05
Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins. J Biol Chem (2004) 1.04
Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin Cancer Res (2005) 1.04
Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells. Prostate (2008) 1.02
Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. Curr Radiopharm (2016) 1.02
Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion. Oncogene (2005) 1.01
Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). J Urol (2011) 1.01
Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J Urol (2006) 0.99
Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol (2012) 0.98
The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. J Biol Chem (2009) 0.98
Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res (2004) 0.97
Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. Biochem Pharmacol (2009) 0.96
Antibody-based therapeutics: focus on prostate cancer. Cancer Metastasis Rev (2005) 0.95
Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol. Cancer Res (2004) 0.95
Microtubules regulate hypoxia-inducible factor-1α protein trafficking and activity: implications for taxane therapy. J Biol Chem (2012) 0.95
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer (2013) 0.94
A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano (2011) 0.94
Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens. Cancer Res (2002) 0.93
Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells. Biochim Biophys Acta (2007) 0.93
Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Cancer (2006) 0.93
Cyclostreptin (FR182877), an antitumor tubulin-polymerizing agent deficient in enhancing tubulin assembly despite its high affinity for the taxoid site. Biochemistry (2005) 0.93
Molecular design and chemical synthesis of a highly potent epothilone. ChemMedChem (2006) 0.91
Farnesyltransferase inhibitors reverse taxane resistance. Cancer Res (2006) 0.90
The hematopoietic-specific beta1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression. Cell Cycle (2009) 0.90
Leptin promotes invasiveness of murine renal cancer cells via extracellular signal-regulated kinases and rho dependent pathway. J Urol (2006) 0.90
Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000. Cancer (2009) 0.89
The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol (2002) 0.89
Synergistic activation of the androgen receptor by bombesin and low-dose androgen. Clin Cancer Res (2002) 0.89
Multiple androgen response elements cooperate in androgen regulated activity of the type 1 neutral endopeptidase promoter. Mol Cell Endocrinol (2006) 0.88
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. Clin Genitourin Cancer (2008) 0.88
The role of HIF1α in renal cell carcinoma tumorigenesis. J Mol Med (Berl) (2014) 0.88
A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer Cell (2016) 0.88
Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies. Cancer Biol Ther (2010) 0.88
Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2. J Biol Chem (2006) 0.88
Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma. Carcinogenesis (2005) 0.87
Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle (2005) 0.87
Exploitation of the HIF axis for cancer therapy. Cancer Biol Ther (2004) 0.85
Clinical utility of radiolabeled monoclonal antibodies in prostate cancer. Clin Genitourin Cancer (2006) 0.84
Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab Chip (2013) 0.84
beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res (2005) 0.84
Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. J Immunother (2007) 0.84
CENP-E checks in microtubule-drug resistance. Cell Cycle (2010) 0.84
Of peptides and peptidases: the role of cell surface peptidases in cancer. Clin Cancer Res (2003) 0.84
Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes. Mol Cancer Ther (2011) 0.84
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. Cancer (2011) 0.83
Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer. Clin Cancer Res (2004) 0.83
Total synthesis and biological evaluation of (-)apicularen A and analogues thereof. Chemistry (2003) 0.82